Navigation Links
Experimental drug achieves unprecedented weight loss
Date:4/10/2011

DURHAM, N.C. An investigational combination of drugs already approved to treat obesity, migraine and epilepsy produced up to a 10 percent weight loss in obese individuals participating in a one-year clinical trial, according to researchers at Duke University Medical Center.

Appearing online in The Lancet today, the study found that treatment with the controlled-release combination therapy consisting of phentermine and topiramate also achieved significant reductions in blood pressure and hemoglobin A1C. Study participants also experienced improvements in cholesterol, triglycerides and inflammatory markers, including C-reactive protein, when taking either of two doses of the combination when compared to placebo.

"Patients receiving this combination experienced 8.6 percent greater weight loss, on average, compared to those patients receiving placebo," says Kishore M. Gadde, M.D., director of Duke's obesity clinical trials program. "This kind of weight loss, coupled with significant reductions in cardiometabolic risk factors represents a potentially important advancement in the management of obesity."

Currently, orlistat is the only drug available for the long-term treatment of obesity. It is marketed in prescription strength as Xenical, and available over the counter as Alli. Meta-analysis studies have shown that treatment with orlistat, at maximum strength, can lead to approximately seven-pound greater weight loss compared to treatment with placebo after one year. "The combination drug achieves about 19 pounds of weight loss relative to placebo at one year," Gadde says.

The 56-week, phase 3 study was conducted in 93 U.S. centers with 2487 patients who had a BMI of 27-45kg/m2, and two or more co-morbidities such as diabetes or heart disease. Patients were randomly assigned to receive either a placebo or one of two low-dose drug combinations. The study tested phentermine, a short-term obesity treatment available since 1
'/>"/>

Contact: Debbe Geiger
debbe.geiger@duke.edu
919-660-9461
Duke University Medical Center
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Science at a glance: Symposia, research and special events at Experimental Biology 2011
2. A new experimental diagnostic test able to quickly distinguish infection from tuberculosis disease
3. Extra Tests Not a Deterrent to Experimental Cancer Therapy
4. 2 Experimental Drugs Show Promise for Rare Pancreatic Cancer
5. Experimental approach may improve healing of diabetic wounds and bed sores
6. Study raises safety concerns about experimental cancer approach
7. First liver transplant patients receive experimental drug to prevent hepatitis C infection
8. Experimental Drug Helps Fight Aggressive Breast Cancer: Report
9. Experimental drug more potent, longer lasting than morphine
10. Experimental vaccine sets sights on lung cancer
11. Experimental Drug Raises Good Cholesterol Levels in Early Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The federal court ... the U.S. District Court, Southern District of West Virginia has ... in that proceeding’s first bellwether trial. In an Order dated ... new trial after finding that C.R. Bard had not proven ...
(Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
(Date:1/22/2015)... As interest in the value of spiritual support as ... Rev. Eric J. Hall , president and CEO of the ... the keynote speaker on January 27 at an international summit ... The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual Care,” ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... patch for current drug both control symptoms better, studies ... new medication and an improved delivery system for an ... symptoms of Parkinson,s disease. , In the first study, ... typical Parkinson,s symptoms, such as tremors and slowness of ...
... June 2008 - Elsevier announced today Reproductive Health ... "Conflict and Crisis Settings: Promoting Sexual and Reproductive rights". ... well as rampant militarism, growing numbers of refugees and ... rights or even ,the right to have rights,. ...
... could someday be used routinely to help paralyzed patients ... Now, University of Florida researchers have taken the concept ... not only to translate brain signals into movement but ... , Instead of simply interpreting brain signals and routing ...
... the medical spa trend but doing little to ... advocate their own safety within the facility, CHICAGO, June ... results from a consumer survey asking 1,000 women,their opinions on ... 2001, are the primary customers of these facilities.,Yet half of ...
... The Rehabilitation Institute,of Chicago and MediCom Worldwide, ... Pain July 18th and 19th. The meeting will ... Northwestern University in Chicago., This year, the ... The scientific agenda will focus on the latest ...
... With a latency period of 10-50,years, and with ... the ravages of this life ending disease continue,to disrupt ... press,conference with leadership, members of Congress and three guest ... to mesothelioma., The press conference will be held ...
Cached Medicine News:Health News:New Hope for Parkinson's Patients 2Health News:May 2008 issue on conflict and crisis settings: Promoting sexual and reproductive rights 2Health News:Researchers develop neural implant that learns with the brain 2Health News:Researchers develop neural implant that learns with the brain 3Health News:Millennials' Medspa Influence 2Health News:3rd Annual Conference on Pain Jointly Sponsored By Rehabilitation Institute of Chicago and MediCom Worldwide, Inc. 2Health News:Faces of Mesothelioma; Meso Foundation Press Conference with Families and Patients 2
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: ... Phase I trial of Lixte,s lead compound, LB‑100, is being ... John S. Kovach , M.D., the founder and ... to be completed at a single site. Accrual of patients, ...
(Date:1/23/2015)... Ala. , Jan. 23, 2015 Gem Pharmaceuticals ... patients have been enrolled into the Company,s Phase 2 ... and safety of Gem,s lead compound, GPX-150 (an investigational ... advanced or metastatic disease. Logo - ...
(Date:1/22/2015)...  Uroplasty, Inc. (NASDAQ: UPI ), a medical device ... to treat voiding dysfunctions, today reported financial results for ... Global revenue for the Company,s Urgent ®  PC ... quarterly revenue record, as compared to $3.9 million in ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... 2, 2011 Lixte Biotechnology Holdings ... company has received a $244,479.25 grant under the ... further development and commercialization of Lixte,s novel anti-cancer compound LB-100. ... Protection and Affordable Care Act of 2010 to encourage development ...
... 2011 Joslin Diabetes Center has launched a groundbreaking ... Joslin, with technology from Forward Health Group, Inc., is ... with the critical capability to extract usefulness out of ... to combine this information with practice improvement support and ...
Cached Medicine Technology:Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government 2Joslin Diabetes Center Launches Initiative to Resolve the Critical Link Connecting Continuing Medical Education (CME) to Sustained Quality Improvement 2Joslin Diabetes Center Launches Initiative to Resolve the Critical Link Connecting Continuing Medical Education (CME) to Sustained Quality Improvement 3
... AQuify provides a completely new level ... and lubrication of both the lens ... This blink-activated product contains sodium hyalunorate, ... tear behavior on the eye. With ...
Lens Plus rewetting drops for soft contact lenses....
Renu rewetting drops soothe your eyes and moisturize soft contact lenses to minimize dryness....
For use to rewet and lubricate lenses during wear. Soothes and moisturizes eyes while wearing soft contact lenses....
Medicine Products: